Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses

Abstract

Coronavirus (CoV) disease 2019 (COVID-19) caused by severe acute respiratory syndrome (SARS)-CoV-2 (also known as 2019-nCoV) is threatening global public health, social stability, and economic development. To meet this challenge, this article discusses advances in the research and development of neutralizing antibodies (nAbs) for the prevention and treatment of infection by SARS-CoV-2 and other human CoVs.

Cited by papers we hold 26

• The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans · 2022
  No notice
• Anti-cancer Therapy Leads to Increased Cardiovascular Susceptibility to COVID-19 · 2021
  Not checked
• Dynamics of neutralizing antibody responses to SARS-CoV-2 in patients with COVID-19: an observational study · 2021
  Not checked
• Therapeutic approaches against coronaviruses acute respiratory syndrome · 2021
  Not checked
• The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates · 2021
  No notice
• COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies · 2021
  No notice
• Systems serology detects functionally distinct coronavirus antibody features in children and elderly · 2021
  No notice
• Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies · 2021
  No notice
• Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant · 2021
  No notice
• The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies · 2020
  No notice
• Potential Therapeutic Options for COVID-19 · 2020
  Not checked
• Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past · 2020
  No notice
• Integrative analyses of SARS-CoV-2 genomes from different geographical locations reveal unique features potentially consequential to host-virus interaction, pathogenesis and clues for novel therapies · 2020
  Not checked
• COVID-19-associated gastrointestinal and liver injury: clinical features and potential mechanisms · 2020
  No notice
• The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens · 2020
  No notice
• The hallmarks of COVID-19 disease · 2020
  No notice
• Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital · 2020
  No notice
• A simple protein-based surrogate neutralization assay for SARS-CoV-2 · 2020
  No notice
• Antibody response to SARS-CoV-2 infection in humans: A systematic review · 2020
  No notice
• Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19 · 2020
  No notice

and 6 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.